Trinity Biotech plc (TRIB)
USD 0.58
(0.33%)
USD 0.58
(0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 56.83 Million USD | -24.0% |
| 2022 | 74.77 Million USD | -19.56% |
| 2021 | 92.96 Million USD | -8.84% |
| 2020 | 101.98 Million USD | 12.77% |
| 2019 | 90.43 Million USD | -6.8% |
| 2018 | 97.03 Million USD | -2.12% |
| 2017 | 99.14 Million USD | -0.47% |
| 2016 | 99.61 Million USD | -0.58% |
| 2015 | 100.19 Million USD | -4.46% |
| 2014 | 104.87 Million USD | 14.97% |
| 2013 | 91.21 Million USD | 10.55% |
| 2012 | 82.51 Million USD | 5.85% |
| 2011 | 77.94 Million USD | -13.04% |
| 2010 | 89.63 Million USD | -28.81% |
| 2009 | 125.9 Million USD | -10.16% |
| 2008 | 140.13 Million USD | -2.42% |
| 2007 | 143.61 Million USD | 21.02% |
| 2006 | 118.67 Million USD | 20.41% |
| 2005 | 98.56 Million USD | 23.29% |
| 2004 | 79.94 Million USD | 21.73% |
| 2003 | 65.67 Million USD | 26.35% |
| 2002 | 51.97 Million USD | 40.24% |
| 2001 | 37.06 Million USD | 24.62% |
| 2000 | 29.74 Million USD | 13.94% |
| 1999 | 26.1 Million USD | 12.52% |
| 1998 | 23.2 Million USD | 38.1% |
| 1997 | 16.8 Million USD | 133.33% |
| 1996 | 7.2 Million USD | -27.27% |
| 1995 | 9.9 Million USD | 90.38% |
| 1994 | 5.2 Million USD | 116.67% |
| 1993 | 2.4 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 15.84 Million USD | 7.75% |
| 2024 Q1 | 14.7 Million USD | 9.5% |
| 2023 Q1 | 14.82 Million USD | -17.78% |
| 2023 Q4 | 13.42 Million USD | -8.51% |
| 2023 Q3 | 14.67 Million USD | 5.61% |
| 2023 Q2 | 13.89 Million USD | -6.28% |
| 2023 FY | 56.83 Million USD | -24.0% |
| 2022 Q2 | 18.46 Million USD | -1.66% |
| 2022 Q4 | 18.03 Million USD | -7.52% |
| 2022 FY | 74.77 Million USD | -19.56% |
| 2022 Q1 | 18.77 Million USD | -3.84% |
| 2022 Q3 | 19.5 Million USD | 5.62% |
| 2021 Q4 | 19.52 Million USD | -11.27% |
| 2021 Q1 | 25.59 Million USD | -21.89% |
| 2021 Q3 | 22 Million USD | -14.86% |
| 2021 FY | 92.96 Million USD | -8.84% |
| 2021 Q2 | 25.84 Million USD | 0.97% |
| 2020 Q2 | 16.02 Million USD | -24.33% |
| 2020 FY | 101.98 Million USD | 12.77% |
| 2020 Q3 | 32.01 Million USD | 99.79% |
| 2020 Q1 | 21.17 Million USD | -0.66% |
| 2020 Q4 | 32.76 Million USD | 2.35% |
| 2019 FY | 90.43 Million USD | -6.8% |
| 2019 Q2 | 22.49 Million USD | 2.14% |
| 2019 Q1 | 22.02 Million USD | -10.19% |
| 2019 Q4 | 21.31 Million USD | -13.32% |
| 2019 Q3 | 24.59 Million USD | 9.32% |
| 2018 Q1 | 23.79 Million USD | -3.07% |
| 2018 Q3 | 23.71 Million USD | -5.16% |
| 2018 Q4 | 24.52 Million USD | 3.42% |
| 2018 Q2 | 25 Million USD | 5.05% |
| 2018 FY | 97.03 Million USD | -2.12% |
| 2017 FY | 99.14 Million USD | -0.47% |
| 2017 Q2 | 25.44 Million USD | 8.12% |
| 2017 Q3 | 25.6 Million USD | 0.61% |
| 2017 Q4 | 24.55 Million USD | -4.11% |
| 2017 Q1 | 23.53 Million USD | -0.61% |
| 2016 Q3 | 26.12 Million USD | -0.61% |
| 2016 FY | 99.61 Million USD | -0.58% |
| 2016 Q2 | 26.28 Million USD | 11.79% |
| 2016 Q1 | 23.51 Million USD | -5.7% |
| 2016 Q4 | 23.68 Million USD | -9.36% |
| 2015 Q1 | 25.24 Million USD | -5.4% |
| 2015 FY | 100.19 Million USD | -4.46% |
| 2015 Q3 | 25.76 Million USD | 6.2% |
| 2015 Q2 | 24.25 Million USD | -3.89% |
| 2015 Q4 | 24.93 Million USD | -3.2% |
| 2014 FY | 104.87 Million USD | 14.97% |
| 2014 Q1 | 25.02 Million USD | -1.69% |
| 2014 Q4 | 26.68 Million USD | -1.77% |
| 2014 Q3 | 27.16 Million USD | 4.45% |
| 2014 Q2 | 26 Million USD | 3.92% |
| 2013 Q4 | 25.45 Million USD | 5.53% |
| 2013 Q1 | 20.32 Million USD | -2.38% |
| 2013 FY | 91.21 Million USD | 10.55% |
| 2013 Q3 | 24.12 Million USD | 13.18% |
| 2013 Q2 | 21.31 Million USD | 4.84% |
| 2012 FY | 82.51 Million USD | 5.85% |
| 2012 Q4 | 20.82 Million USD | -0.13% |
| 2012 Q3 | 20.85 Million USD | 0.2% |
| 2012 Q2 | 20.8 Million USD | 3.91% |
| 2012 Q1 | 20.02 Million USD | 0.06% |
| 2011 Q4 | 20.01 Million USD | 0.94% |
| 2011 Q3 | 19.82 Million USD | 1.91% |
| 2011 Q1 | 18.65 Million USD | -3.08% |
| 2011 Q2 | 19.45 Million USD | 4.29% |
| 2011 FY | 77.94 Million USD | -13.04% |
| 2010 Q2 | 22.62 Million USD | -22.01% |
| 2010 Q1 | 29.01 Million USD | -5.78% |
| 2010 Q3 | 18.74 Million USD | -17.14% |
| 2010 Q4 | 19.24 Million USD | 2.66% |
| 2010 FY | 89.63 Million USD | -28.81% |
| 2009 Q1 | 31.1 Million USD | -8.54% |
| 2009 FY | 125.9 Million USD | -10.16% |
| 2009 Q2 | 32.3 Million USD | 3.84% |
| 2009 Q3 | 31.7 Million USD | -1.85% |
| 2009 Q4 | 30.79 Million USD | -2.87% |
| 2008 Q2 | 36.29 Million USD | 5.96% |
| 2008 Q3 | 35.58 Million USD | -1.97% |
| 2008 Q4 | 34 Million USD | -4.42% |
| 2008 FY | 140.13 Million USD | -2.42% |
| 2008 Q1 | 34.25 Million USD | -1.39% |
| 2007 Q3 | 34.73 Million USD | -7.21% |
| 2007 Q4 | 34.73 Million USD | 0.01% |
| 2007 Q2 | 37.43 Million USD | 1.98% |
| 2007 Q1 | 36.7 Million USD | 10.14% |
| 2007 FY | 143.61 Million USD | 21.02% |
| 2006 Q2 | 27.31 Million USD | 10.52% |
| 2006 Q1 | 24.71 Million USD | -10.91% |
| 2006 Q3 | 33.31 Million USD | 21.99% |
| 2006 Q4 | 33.32 Million USD | 0.03% |
| 2006 FY | 118.67 Million USD | 20.41% |
| 2005 Q3 | 26.87 Million USD | 18.34% |
| 2005 Q2 | 22.71 Million USD | 7.0% |
| 2005 Q1 | 21.22 Million USD | -3.72% |
| 2005 FY | 98.56 Million USD | 23.29% |
| 2005 Q4 | 27.74 Million USD | 3.21% |
| 2004 Q4 | 22.04 Million USD | 2.8% |
| 2004 Q1 | 16.37 Million USD | 5.77% |
| 2004 Q2 | 20.07 Million USD | 22.56% |
| 2004 Q3 | 21.44 Million USD | 6.86% |
| 2004 FY | 79.94 Million USD | 21.73% |
| 2003 Q3 | 16.91 Million USD | 0.96% |
| 2003 Q4 | 15.48 Million USD | -8.47% |
| 2003 Q1 | 16.52 Million USD | 10.25% |
| 2003 FY | 65.67 Million USD | 26.35% |
| 2003 Q2 | 16.75 Million USD | 1.42% |
| 2002 FY | 51.97 Million USD | 40.24% |
| 2002 Q2 | 11.75 Million USD | 3.02% |
| 2002 Q3 | 13.82 Million USD | 17.54% |
| 2002 Q1 | 11.41 Million USD | 16.46% |
| 2002 Q4 | 14.98 Million USD | 8.42% |
| 2001 FY | 37.06 Million USD | 24.62% |
| 2001 Q4 | 9.8 Million USD | 2.73% |
| 2001 Q3 | 9.54 Million USD | 1.22% |
| 2001 Q2 | 9.42 Million USD | 13.57% |
| 2001 Q1 | 8.29 Million USD | 5.17% |
| 2000 Q2 | 7.4 Million USD | 8.04% |
| 2000 Q1 | 6.85 Million USD | 3.72% |
| 2000 Q3 | 7.6 Million USD | 2.7% |
| 2000 FY | 29.74 Million USD | 13.94% |
| 2000 Q4 | 7.89 Million USD | 3.81% |
| 1999 Q2 | 6.5 Million USD | 1.56% |
| 1999 Q4 | 6.6 Million USD | 0.07% |
| 1999 FY | 26.1 Million USD | 12.52% |
| 1999 Q1 | 6.4 Million USD | 1.59% |
| 1999 Q3 | 6.6 Million USD | 1.54% |
| 1998 Q2 | 5.5 Million USD | 0.0% |
| 1998 FY | 23.2 Million USD | 38.1% |
| 1998 Q3 | 5.8 Million USD | 5.45% |
| 1998 Q1 | 5.5 Million USD | 19.57% |
| 1998 Q4 | 6.3 Million USD | 8.62% |
| 1997 Q2 | 4.1 Million USD | 32.26% |
| 1997 Q3 | 5 Million USD | 21.95% |
| 1997 FY | 16.8 Million USD | 133.33% |
| 1997 Q4 | 4.6 Million USD | -8.0% |
| 1997 Q1 | 3.1 Million USD | 34.78% |
| 1996 Q1 | 1.5 Million USD | -40.0% |
| 1996 Q4 | 2.3 Million USD | 21.05% |
| 1996 Q3 | 1.9 Million USD | 26.67% |
| 1996 FY | 7.2 Million USD | -27.27% |
| 1996 Q2 | 1.5 Million USD | 0.0% |
| 1995 Q2 | 2.4 Million USD | -4.0% |
| 1995 Q3 | 2.5 Million USD | 4.17% |
| 1995 FY | 9.9 Million USD | 90.38% |
| 1995 Q4 | 2.5 Million USD | 0.0% |
| 1995 Q1 | 2.5 Million USD | 0.0% |
| 1994 Q3 | 1.7 Million USD | 0.0% |
| 1994 FY | 5.2 Million USD | 116.67% |
| 1994 Q2 | 1.7 Million USD | 183.33% |
| 1994 Q1 | 600 Thousand USD | 0.0% |
| 1993 Q4 | 600 Thousand USD | 0.0% |
| 1993 Q2 | 600 Thousand USD | 0.0% |
| 1993 FY | 2.4 Million USD | 0.0% |
| 1993 Q3 | 600 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aspira Women's Health Inc. | 9.15 Million USD | -520.843% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -2144.108% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -1726.35% |
| Standard BioTools Inc. | 106.34 Million USD | 46.556% |
| Inotiv, Inc. | 572.42 Million USD | 90.072% |
| Prenetics Global Limited | 21.74 Million USD | -161.385% |
| Neuronetics, Inc. | 71.34 Million USD | 20.345% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -24.128% |
| Castle Biosciences, Inc. | 219.78 Million USD | 74.142% |
| Psychemedics Corporation | 22.09 Million USD | -157.182% |
| RadNet, Inc. | 1.61 Billion USD | 96.485% |
| Exact Sciences Corporation | 2.49 Billion USD | 97.727% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 98.448% |
| iSpecimen Inc. | 9.92 Million USD | -472.431% |
| OpGen, Inc. | 3.41 Million USD | -1562.571% |
| Exagen Inc. | 52.54 Million USD | -8.153% |
| Bionano Genomics, Inc. | 36.11 Million USD | -57.36% |
| CareDx, Inc | 280.32 Million USD | 79.726% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | 81.841% |
| Guardant Health, Inc. | 563.94 Million USD | 89.922% |
| Biodesix, Inc. | 49.08 Million USD | -15.778% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -481.651% |
| Precipio, Inc. | 15.19 Million USD | -273.969% |
| Natera, Inc. | 1.08 Billion USD | 94.75% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 80.349% |
| Sera Prognostics, Inc. | 306 Thousand USD | -18472.549% |
| 23andMe Holding Co. | 219.63 Million USD | 74.125% |
| OPKO Health, Inc. | 863.49 Million USD | 93.418% |
| Personalis, Inc. | 73.48 Million USD | 22.658% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -81.868% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -325.152% |
| T2 Biosystems, Inc. | 7.19 Million USD | -690.101% |
| Neogen Corporation | 924.22 Million USD | 93.851% |
| Myriad Genetics, Inc. | 678.4 Million USD | 91.623% |
| ICON Public Limited Company | 8.12 Billion USD | 99.3% |
| NeoGenomics, Inc. | 591.64 Million USD | 90.394% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -24.128% |
| MDxHealth SA | 70.19 Million USD | 19.035% |
| Prenetics Global Limited | 21.74 Million USD | -161.385% |
| Illumina, Inc. | 4.5 Billion USD | 98.738% |
| DarioHealth Corp. | 20.35 Million USD | -179.245% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 96.986% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -6246.547% |
| Sotera Health Company | 1.04 Billion USD | 94.584% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -2144.108% |